A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH (NCT07221227)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Chandler, Arizona
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (91 Sites)
Showing the first 25 of 91 sites.
- GSK Investigational Site — Chandler, Arizona
- GSK Investigational Site — Tucson, Arizona
- GSK Investigational Site — Little Rock, Arkansas
- GSK Investigational Site — Arcadia, California
- GSK Investigational Site — Covina, California
- GSK Investigational Site — Folsom, California
- GSK Investigational Site — Los Angeles, California
- GSK Investigational Site — Montclair, California
- GSK Investigational Site — Riverdale, California
- GSK Investigational Site — San Diego, California
- GSK Investigational Site — Santa Maria, California
- GSK Investigational Site — Van Nuys, California
- GSK Investigational Site — Colorado Springs, Colorado
- GSK Investigational Site — Boynton Beach, Florida
- GSK Investigational Site — Cape Coral, Florida
- GSK Investigational Site — Clermont, Florida
- GSK Investigational Site — Fort Myers, Florida
- GSK Investigational Site — Hialeah, Florida
- GSK Investigational Site — Hialeah, Florida
- GSK Investigational Site — Homestead, Florida
- GSK Investigational Site — Inverness, Florida
- GSK Investigational Site — Jacksonville, Florida
- GSK Investigational Site — Kissimmee, Florida
- GSK Investigational Site — Lakeland, Florida
- GSK Investigational Site — Maitland, Florida
📞 Contact the Study Coordinator
Phone: (877) 379-3718
Email: GSKClinicalSupportHD@gsk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-alcoholic Fatty Liver Disease
- Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis — Chula Vista, California
- Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk — St Louis, Missouri
- A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) — Chandler, Arizona
- A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) — Birmingham, Alabama
- SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease — Chicago, Illinois
- The Olmsted NAFLD Epidemiology Study (TONES) — Rochester, Minnesota
Explore by condition: All Non-alcoholic Fatty Liver Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.